Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Capecitabine in combination with Trastuzumab and Tucatinib in patients with Invasive Breast Carcinoma.

Statements

Source and description
Tukysa (tucatinib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to tucatinib in combination with trastuzumab and capecitabine for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.
Tukysa (tucatinib) [product monograph]. HC. Health Canada approved tucatinib in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.